| Bioactivity | sFTX-3.3 is a Ca2+ channel antagonist with IC50s of approximately 0.24 mM and 0.70 mM against P-type and N-type channels[1][2]. |
| Invitro | sFTX-3.3 (100 μM) reduces the duration of the slow component of presynaptic calcium currents by about 50% of the control and also reduces presynaptic sodium current by approximately 20% of the control. sFTX-3.3 (100 μM) reduces whole-cell sodium current recorded from SK.N.SH cells by approximately 15%[3]. |
| Name | sFTX-3.3 |
| CAS | 141997-14-0 |
| Formula | C12H29N7O |
| Molar Mass | 287.40 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Maria Elisa Calcagnotto, et al. An examination of calcium current function on heterotopic neurons in hippocampal slices from rats exposed to methylazoxymethanol. Epilepsia. 2003 Mar;44(3):315-21. [2]. T M Norris, et al. Block of high-threshold calcium channels by the synthetic polyamines sFTX-3.3 and FTX-3.3. Mol Pharmacol. 1996 Oct;50(4):939-46. [3]. M Fatehi, et al. Polyamine FTX-3.3 and polyamine amide sFTX-3.3 inhibit presynaptic calcium currents and acetylcholine release at mouse motor nerve terminals. Neuropharmacology. 1997 Feb;36(2):185-94. |